skip to main content

Palivizumab – RSV prevention — RACP Paediatrics MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRespiratoryPalivizumab – RSV preventionRACP Paediatrics

A premature infant (28 weeks) is being discharged from NICU at the start of winter (May in Australia). He has chronic lung disease (still on home oxygen). What specific passive immunisation should be considered for RSV prevention?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Palivizumab (RSV prophylaxis)

Palivizumab (anti-RSV monoclonal antibody) is recommended for high-risk infants including those with CLD of prematurity (<32 weeks with ongoing oxygen/respiratory support) during RSV season. It is given as monthly IM injections throughout the RSV season. Nirsevimab (longer-acting single-dose mAb) is an emerging alternative now available in Australia.

Reference: RCH Melbourne – 2023 – RSV Prophylaxis CPG; Australian Immunisation Handbook – 2024